Visterra Revenue and Competitors

Boston, MA USA

Location

$125.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Visterra's estimated annual revenue is currently $28.9M per year.(i)
  • Visterra's estimated revenue per employee is $193,750
  • Visterra's total funding is $125.4M.

Employee Data

  • Visterra has 149 Employees.(i)
  • Visterra grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Visterra discovers and develops novel drugs utilizing its proprietary platform based on the atomic interaction network analyses of proteins. The company's innovative technology platform enables a more in depth, three-dimensional structural understanding of proteins to (i) identify unique target epitopes and (ii) guide the design of novel drugs to effectively combat disease. The company has established proof-of-concept with its lead product candidate, VIS410, a monoclonal antibody which represents a significant advancement in the treatment and prevention of both seasonal and pandemic influenza. VIS410 is also an important validation of the broad potential of Visterra's technology platform. The company is building a proprietary pipeline of novel drugs targeting infectious diseases. Through a coalition of partners with a shared mission – including U.S. and non-U.S. governments, global foundations and pharmaceutical companies – Visterra is committed to providing safe and effective therapies to patients in both the developed and developing world.

keywords:N/A

$125.4M

Total Funding

149

Number of Employees

$28.9M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Visterra News

2022-04-17 - Local Event: 2nd Fc Receptor & IgG Targeted Therapies Summit

... Dariush Mohammadyani Senior Scientist Janssen Pharmaceuticals, Karthik Viswanathan Director of Research Visterra, Alyson Smith Associate...

2022-04-17 - Boswellia Serrata Extract Market Size, Share, Growth 2022 ...

Visterra; Health Genesis; Xian Longze Biotechnology; Wuhan Vanz Pharm; Organic Herb; Herbasian industries Pakistan; Xi'an Lyphar Biotech; Xi'an...

2022-04-06 - Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

... R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.4M149-6%N/A
#2
$41.1M14931%N/A
#3
$33.8M150-9%N/A
#4
$24.1M1511%N/A
#5
$23.4M15130%N/A